Latest Market Uncertainty News

Mirrabooka Investments reported a 63.6% jump in net profit to $13 million for FY26, boosted by higher investment income and dividends. However, its portfolio lagged the benchmark, dragged down by sector exposures and tech stock de-ratings.

Cadence Opportunities Fund (ASX:CDO) has announced a fully franked final dividend of 7.5 cents per share and a special dividend of 2 cents following a 30.3% return for FY26, boosting its yield to 6.5%.

Rua Bioscience has secured its largest export contract, committing to supply New Zealand-grown medical cannabis flower to a major UK distributor, projecting over NZ$10 million in revenue across two years.

Atomos Limited has trimmed its FY26 sales guidance to approximately $40 million due to softer end-consumer demand and delayed product shipments, while forecasting EBITDA between $2.5 million and $3.5 million supported by improved margins.

KKR Credit Income Fund (ASX:KKC) has confirmed its distribution guidance for FY2027, maintaining a monthly payout of 1.67 cents per unit and an annualised yield above 8%.

DigitalX Limited is initiating an on-market buy-back of up to 120 million shares, representing about 10% of its smallest share count in the past year. The move aims to leverage the current undervaluation and enhance shareholder value.

CD Private Equity Fund III (ASX:CD3) posted a net loss of $9.01 million for FY26, weighed down by foreign exchange losses and fair value declines. Despite near-term challenges, the Fund sustains strong long-term performance and liquidity.

Turners Automotive Group posted a record $63.2 million normalised NPBT for FY26, beating guidance and declaring a 14% higher dividend as it accelerates branch expansion and ecosystem integration.

Canadian Phosphate (ASX: CP8) secured $5.2 million through a rights issue and follow-on placement, positioning itself to accelerate exploration and development across key projects in Canada and the US.

Australian Foundation Investment Company (ASX:AFI) plans a fully franked 14.5 cents per share final dividend alongside a 2.5 cents special dividend, subject to market conditions, while maintaining its on-market share buy-back.

Buru Energy has launched a prospectus offering over 207 million new options free-attaching to a recent $5.3 million placement, aiming to back the commercialisation of its Rafael Gas Project and bolster working capital.

Cynata Therapeutics (ASX: CYP) has had its trading suspension lifted immediately following the publication of results from its Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease clinical trials.